GSK (GSK LN) Q1 2026 (GBP) Adj. EPS 46.5p (exp. 43.2p), Turnover 7.63bln (prev. 7.51bln Y/Y), Gross Profit 1.87bln (prev. 1.93bln Y/Y); reaffirms 2026 guidance

GSK's Q1 results exceeded EPS expectations, reflecting strong performance in Specialty Medicines and a stable turnover growth year-over-year.

Newsquawk StaffPublished 29 Apr 2026, 06:20 UTCOn the live feed at 06:00 UTC — 2 more headlines followed before this page went public

Newsquawk headlinesUTC

06:06

Lloyds (LLOY LN) Q1 2026 (GBP): Statutory Pretax Profit 2.03bln (exp. 1.78bln), NII 3.56bln (prev. 3.29bln Y/Y), EPS 2.4p (prev. 1.7p Y/Y); reiterated guidance

06:03

TotalEnergies (TTE FP) Q1 2026 (USD): adj. Net 5.39bln (exp. 4.98bln), Cash Flow 8.6bln (prev. 7.2bln Q/Q), Net income 5.8bln (prev. 2.9bln Q/Q), adj. EBITDA 12.6bln (prev. 10.1bln Q/Q). To continue buybacks.

06:00

GSK (GSK LN) Q1 2026 (GBP) Adj. EPS 46.5p (exp. 43.2p), Turnover 7.63bln (prev. 7.51bln Y/Y), Gross Profit 1.87bln (prev. 1.93bln Y/Y); reaffirms 2026 guidance

05:18

Newsquawk Daily European Opening News - 29th April 2026

05:06

LG Electronics (066570 KS) Q1 2026 (KRW): Net 815.7bln (exp. 801.1bln), Operating profit 1.67tln, Revenue 23.7tln

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Others:

Speciality Medicines 3.2bln, Vaccines 2.1bln. Specialty Medicines +14% Y/Y; Respiratory, Immunology & Inflammation 0.9bln (+16%), Oncology 0.5bln (+28%), HIV 1.8bln (+10%).
Vaccines +4% Y/Y; Shingrix 1.0bln (+20%), Meningitis vaccines 0.3bln (-3%), Arexvy 0.1bln (-18%).

Dividend:

Q1 2026 dividend of 17p declared; 70p expected for full year 2026.
GBP 1.7bln executed to date as part of the GBP 2bln share buyback programme announced at FY2024.

Guidance:

Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9%.
2031 sales outlook of more than GBP 40bln.

Context

The reaffirmation of 2026 guidance suggests confidence in ongoing revenue expansion, particularly with a solid growth outlook and share buyback initiatives, which could positively influence sentiment among investors as they weigh long-term prospects.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/8 Sept · 11:48 UTC

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations.

Market, after we published+1.0%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.